MDxHealth SA (MDXH.BR)

BE0974461940 - Common Stock

3.02  -0.12 (-3.76%)

Fundamental Rating

2

MDXH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 74 industry peers in the Biotechnology industry. MDXH has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, MDXH is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

MDXH had negative earnings in the past year.
In the past 5 years MDXH always reported negative net income.
MDXH had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

MDXH's Return On Assets of -51.61% is on the low side compared to the rest of the industry. MDXH is outperformed by 63.64% of its industry peers.
MDXH has a Return On Equity of -393.48%. This is in the lower half of the industry: MDXH underperforms 75.32% of its industry peers.
Industry RankSector Rank
ROA -51.61%
ROE -393.48%
ROIC N/A
ROA(3y)-55.15%
ROA(5y)-64.23%
ROE(3y)-343.17%
ROE(5y)-262.12%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

MDXH has a Gross Margin of 59.66%. This is in the better half of the industry: MDXH outperforms 64.94% of its industry peers.
In the last couple of years the Gross Margin of MDXH has declined.
MDXH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 59.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-6.79%

2

2. Health

2.1 Basic Checks

MDXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MDXH has been increased compared to 1 year ago.
MDXH has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MDXH is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -3.05, we must say that MDXH is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MDXH (-3.05) is worse than 71.43% of its industry peers.
A Debt/Equity ratio of 2.17 is on the high side and indicates that MDXH has dependencies on debt financing.
MDXH has a worse Debt to Equity ratio (2.17) than 75.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.17
Debt/FCF N/A
Altman-Z -3.05
ROIC/WACCN/A
WACC6.93%

2.3 Liquidity

MDXH has a Current Ratio of 2.43. This indicates that MDXH is financially healthy and has no problem in meeting its short term obligations.
MDXH has a Current ratio (2.43) which is comparable to the rest of the industry.
A Quick Ratio of 2.27 indicates that MDXH has no problem at all paying its short term obligations.
MDXH has a Quick ratio of 2.27. This is comparable to the rest of the industry: MDXH outperforms 44.16% of its industry peers.
Industry RankSector Rank
Current Ratio 2.43
Quick Ratio 2.27

5

3. Growth

3.1 Past

MDXH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.81%.
The Revenue has grown by 66.59% in the past year. This is a very strong growth!
MDXH shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.77% yearly.
EPS 1Y (TTM)-16.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
Revenue 1Y (TTM)66.59%
Revenue growth 3Y46.47%
Revenue growth 5Y-1.77%
Sales Q2Q%73.48%

3.2 Future

The Earnings Per Share is expected to grow by 51.91% on average over the next years. This is a very strong growth
Based on estimates for the next years, MDXH will show a very strong growth in Revenue. The Revenue will grow by 27.69% on average per year.
EPS Next Y-6519.8%
EPS Next 2Y-619.83%
EPS Next 3Y-49.87%
EPS Next 5Y51.91%
Revenue Next Year84.81%
Revenue Next 2Y47.5%
Revenue Next 3Y43.11%
Revenue Next 5Y27.69%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

0

4. Valuation

4.1 Price/Earnings Ratio

MDXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDXH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

MDXH's earnings are expected to decrease with -49.87% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-619.83%
EPS Next 3Y-49.87%

0

5. Dividend

5.1 Amount

MDXH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

MDxHealth SA

EBR:MDXH (12/15/2023, 7:00:00 PM)

3.02

-0.12 (-3.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap82.41M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -51.61%
ROE -393.48%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 59.66%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 2.17
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.43
Quick Ratio 2.27
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-16.81%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-6519.8%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)66.59%
Revenue growth 3Y46.47%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y